Related references
Note: Only part of the references are listed.Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function
Lydia Dyck et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2022)
Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals
Ji-Won Seo et al.
SCIENCE ADVANCES (2022)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
Body surface area capping may not improve cytotoxic drugs tolerance
Wafa Bouleftour et al.
SCIENTIFIC REPORTS (2021)
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update
Jennifer J. Griggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Next generation of immune checkpoint inhibitors and beyond
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies
Meysam Zarezadeh et al.
EUROPEAN JOURNAL OF NUTRITION (2021)
The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients
Yuyan Pan et al.
BMC INFECTIOUS DISEASES (2020)
Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Yue An et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement
Shuangshuang Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: A pooled analysis of 4090 cancer patients
Huilin Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
Ziming Wang et al.
NATURE MEDICINE (2019)
Obesity and chemotherapy administration: between empiric and mathematic method review
W. Bouleftour et al.
ACTA ONCOLOGICA (2019)
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525
H. Ian Robins et al.
NEURO-ONCOLOGY PRACTICE (2019)
Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine
Femke M. de Man et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study
Gertraud Stocker et al.
EUROPEAN JOURNAL OF CANCER (2018)
Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters
Cornelis Smit et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Secretion of autoimmune antibodies in the human subcutaneous adipose tissue
Daniela Frasca et al.
PLOS ONE (2018)
The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436)
Vicki A. Morrison et al.
JOURNAL OF GERIATRIC ONCOLOGY (2018)
Fixed Dosing of Monoclonal Antibodies in Oncology
Jeroen J. M. A. Hendrikx et al.
ONCOLOGIST (2017)
Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide
Sjoerd de Hoogd et al.
CLINICAL PHARMACOKINETICS (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically III Patients
Abdulaziz S. Alobaid et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors
M. Ahamadi et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Body composition and anti-neoplastic treatment in adult and older subjects - A systematic review
Stephane Gerard et al.
JOURNAL OF NUTRITION HEALTH & AGING (2016)
Universal equation for estimating ideal body weight and body weight at any BMI
Courtney M. Peterson et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2016)
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study
J. Furlanetto et al.
ANNALS OF ONCOLOGY (2016)
Myelosuppression by chemotherapy in obese patients with gynecological cancers
Kensuke Kamimura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer
H. Lote et al.
CLINICAL ONCOLOGY (2016)
Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen
Anne van Rongen et al.
CLINICAL PHARMACOKINETICS (2016)
Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients
Henry Chan et al.
LEUKEMIA & LYMPHOMA (2016)
Time Varying Apparent Volume of Distribution and Drug Half-Lives Following Intravenous Bolus Injections
Carl A. Wesolowski et al.
PLOS ONE (2016)
Body surface area formulae: an alarming ambiguity
Grzegorz Redlarski et al.
SCIENTIFIC REPORTS (2016)
Comparison of two different formulas for body surface area in adults at extremes of height and weight
Karen M. Fancher et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome
Gino Seravalle et al.
HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION (2016)
Altered Morphine Glucuronide and Bile Acid Disposition in Patients With Nonalcoholic Steatohepatitis
B. C. Ferslew et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients
Jean Hansen et al.
GYNECOLOGIC ONCOLOGY (2015)
Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies
Neil S. Horowitz et al.
GYNECOLOGIC ONCOLOGY (2015)
Principles of chemotherapy
Elisabeth Avail Lundqvist et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2015)
Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus Infections
Eyob D. Adane et al.
PHARMACOTHERAPY (2015)
Drug Dosing and Pharmacokinetics in Children With Obesity A Systematic Review
Margreet W. Harskamp-van Ginkel et al.
JAMA PEDIATRICS (2015)
Association of Body Composition with Outcome of Docetaxel Chemotherapy in Metastatic Prostate Cancer: A Retrospective Review
Weixin Wu et al.
PLOS ONE (2015)
Suboptimal dosing of rituximab in male and female patients with DLBCL
Michael Pfreundschuh et al.
BLOOD (2014)
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
Arun Ganti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
The Scientific Basis of Body Surface Area-Based Dosing
E. Chatelut et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
An Approach to Chemotherapy-Associated Toxicity
Zhanna Livshits et al.
EMERGENCY MEDICINE CLINICS OF NORTH AMERICA (2014)
Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis
Margreke J. E. Brill et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Pharmacokinetics of Human Chorionic Gonadotropin Injection in Obese and Normal-Weight Women
Divya K. Shah et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Impact on Survival and Toxicity by Duration of Weight Extremes During Treatment for Pediatric Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Etan Orgel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Obesity and Cardiovascular Diseases
Carl J. Lavie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women
James P. Carroll et al.
MEDICAL ONCOLOGY (2014)
Broad-spectrum β-lactams in obese non-critically ill patients
M. Hites et al.
NUTRITION & DIABETES (2014)
Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis
K. C. Hourdequin et al.
ANNALS OF ONCOLOGY (2013)
Case-Control Study of Drug Monitoring of β-Lactams in Obese Critically Ill Patients
Maya Hites et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Impact of Obesity and the Obesity Paradox on Prevalence and Prognosis in Heart Failure
Carl J. Lavie et al.
JACC-HEART FAILURE (2013)
Chemotherapy dose reductions in obese patients with colorectal cancer
P. Chambers et al.
ANNALS OF ONCOLOGY (2012)
Impact of Obesity on Drug Metabolism and Elimination in Adults and Children
Margreke J. E. Brill et al.
CLINICAL PHARMACOKINETICS (2012)
Dosing of antibiotics in obesity
Brett Janson et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2012)
Fixed Dosing Versus Body Size-Based Dosing of Therapeutic Peptides and Proteins in Adults
Shuzhong Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Jennifer J. Griggs et al.
JOURNAL OF ONCOLOGY PRACTICE (2012)
Busulfan Dosing in Children with BMIs ≥85% Undergoing HSCT: A New Optimal Strategy
Britton Browning et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Altered xanthine oxidase and N-acetyltransferase activity in obese children
Manoj S. Chiney et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity
Carla M. M. Prado et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Overweight as a Prognostic Factor in Children With Acute Lymphoblastic Leukemia
Cristina B. Gelelete et al.
OBESITY (2011)
Measurement of Glomerular Filtration Rate in Obese Patients: Pitfalls and Potential Consequences on Drug Therapy
Gregoire Wuerzner et al.
OBESITY FACTS (2011)
Dose-Dependent Delay of the Hypoglycemic Effect of Short-Acting Insulin Analogs in Obese Subjects With Type 2 Diabetes A pharmacokinetic and pharmacodynamic study
Maude Gagnon-Auger et al.
DIABETES CARE (2010)
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
Patrick A. Thompson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Corine Ekhart et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Adipocytes Impair Leukemia Treatment in Mice
James W. Behan et al.
CANCER RESEARCH (2009)
Advances in Cancer Therapeutics
A. Sparreboom et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
Diane D. Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Obesity and Cardiovascular Disease Risk Factor, Paradox, and Impact of Weight Loss
Carl J. Lavie et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Gary H. Lyman
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Hepatic microcirculation in fatty liver disease
Geoff C. Farrell et al.
ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY (2008)
Obesity and cancer treatment: Weighing the evidence
Jennifer J. Griggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemotherapy Dosing Strategies in the Obese, Elderly, and Thin Patient: Results of a Nationwide Survey
Kathryn M. Field et al.
JOURNAL OF ONCOLOGY PRACTICE (2008)
Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study
Gillian K. Reeves et al.
BRITISH MEDICAL JOURNAL (2007)
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese
Alex Sparreboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Obesity and outcome in pediatric acute lymphoblastic leukemia
Anna M. Butturini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Obesity and obesity-initiated metabolic syndrome: Mechanistic links to chronic kidney disease
Ihab M. Wahba et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy
Jennifer J. Griggs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient
Carina Ritzmo et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2007)
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia
Nobuko Hijiya et al.
BLOOD (2006)
Obesity is associated with family history of ESRD in incident dialysis patients
Rebecca A. Speckman et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients
JE Latz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
L Nguyen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Body mass index and risk for end-stage renal disease
CY Hsu et al.
ANNALS OF INTERNAL MEDICINE (2006)
Obesity and risk for chronic renal failure
Elisabeth Ejerblad et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Obesity-related glomerulopathy: Insights from gene expression profiles of the glomeruli derived from renal biopsy samples
YC Wu et al.
ENDOCRINOLOGY (2006)
Undertreatment of obese women receiving breast cancer chemotherapy
JJ Griggs et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients
JP Ong et al.
OBESITY SURGERY (2005)
Anesthesia in the obese patient: Pharmacokinetic considerations
A Casati et al.
JOURNAL OF CLINICAL ANESTHESIA (2005)
Mortality in overweight and children with acute myeloid underweight leukemia
BJ Lange et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Body mass index and the risk of development of end-stage renal disease in a screened cohort
K Iseki et al.
KIDNEY INTERNATIONAL (2004)
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study
GH Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices
GH Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The 3D scanner for measuring body surface area: a simplified calculation in the Chinese adult
CY Yu et al.
APPLIED ERGONOMICS (2003)
Dosing strategies for anticancer drugs: the good, the bad and body-surface area
A Felici et al.
EUROPEAN JOURNAL OF CANCER (2002)
Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin
ME de Jonge et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Obesity and the risk of heart failure
S Kenchaiah et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Body surface area as a determinant of pharmacokinetics and drug dosing
M Sawyer et al.
INVESTIGATIONAL NEW DRUGS (2001)
Effects of obesity on pharmacokinetics - Implications for drug therapy
G Cheymol
CLINICAL PHARMACOKINETICS (2000)
Drug-like properties and the causes of poor solubility and poor permeability
CA Lipinski
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2000)
Glomerular hemodynamics in severe obesity
A Chagnac et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2000)
Share Paper
